Vasoconstrictor and Pressor Effects of Des-Aspartate-Angiotensin I in Rat
Metadatos
Mostrar el registro completo del ítemAutor
Wangensteen, Rosemary; Gómez Guzmán, Manuel; Banegas, Inmaculada; Rodríguez-Gómez, Isabel; Jiménez, Rosario; Duarte, Juan; García-Estañ, Joaquín; Vargas, FélixEditorial
MDPI
Materia
renin-angiotensin system des-aspartate-angiotensin I vascular reactivity
Fecha
2022-05-25Referencia bibliográfica
Wangensteen, R. et. al. Biomedicines 2022, 10, 1230. [https://doi.org/10.3390/biomedicines10061230]
Patrocinador
Carlos III Health Institute of Spain grant number PI18/01715 and the Cooperative Research Network RICORS2040, RD21/0005/0015 “FEDER a way to make Europe”Resumen
This study investigated the vasoactive effects of des-aspartate-angiotensin-I (DAA-I) in
male Wistar rats on whole body vascular bed, isolated perfused kidneys, and aortic rings. Dose–
response curves to DAA-I were compared with those to angiotensin II (Ang II). The Ang II-type-1
(AT1) receptor blocker, losartan, was used to evaluate the role of AT1 receptors in the responses
to DAA-I. Studies were also conducted of the responsiveness in aortic rings after endothelium
removal, nitric oxide synthase inhibition, or AT2 receptor blockade. DAA-I induced a dose-related
systemic pressor response that was shifted to the right compared with Ang II. Losartan markedly
attenuated the responsiveness to DAA-I. DAA-I showed a similar pattern in renal vasculature
and aortic rings. In aortic rings, removal of endothelium and nitric oxide inhibition increased the
sensitivity and maximal response to DAA-I and Ang II. AT2 receptor blockade did not significantly
affect the responsiveness to DAA-I. According to these findings, DAA-I increases the systemic
blood pressure and vascular tone in conductance and resistance vessels via AT1 receptor activation.
This vasoconstrictor effect of DAA-I participates in the homeostatic control of arterial pressure,
which can also contribute to the pathogenesis of hypertension. DAA-I may therefore be a potential
therapeutic target in cardiovascular disease.